image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.7382
-1.01 %
$ 22.9 M
Market Cap
-1.23
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one DRRX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.738 USD, DURECT Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one DRRX stock under the base case scenario is HIDDEN Compared to the current market price of 0.738 USD, DURECT Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one DRRX stock under the best case scenario is HIDDEN Compared to the current market price of 0.738 USD, DURECT Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DRRX

image
$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
2.03 M REVENUE
-76.24%
-18.9 M OPERATING INCOME
48.73%
-8.32 M NET INCOME
69.87%
-19.1 M OPERATING CASH FLOW
44.54%
18 M INVESTING CASH FLOW
1647.51%
-16.3 M FINANCING CASH FLOW
-79.75%
-3.89 M REVENUE
-202.08%
-5.82 M OPERATING INCOME
-46.81%
7.3 M NET INCOME
270.46%
-5.52 M OPERATING CASH FLOW
-75.78%
18 M INVESTING CASH FLOW
1508.13%
-10.6 M FINANCING CASH FLOW
-393.19%
Balance Sheet DURECT Corporation
image
Current Assets 13.2 M
Cash & Short-Term Investments 11.8 M
Receivables 453 K
Other Current Assets 919 K
Non-Current Assets 5.17 M
Long-Term Investments 0
PP&E 2.18 M
Other Non-Current Assets 3 M
64.33 %5.01 %11.86 %16.34 %Total Assets$18.3m
Current Liabilities 7.71 M
Accounts Payable 309 K
Short-Term Debt 1.08 M
Other Current Liabilities 6.32 M
Non-Current Liabilities 1.51 M
Long-Term Debt 1.12 M
Other Non-Current Liabilities 384 K
3.35 %11.74 %68.55 %12.19 %4.17 %Total Liabilities$9.2m
EFFICIENCY
Earnings Waterfall DURECT Corporation
image
Revenue 2.03 M
Cost Of Revenue 78 K
Gross Profit 1.95 M
Operating Expenses 20.9 M
Operating Income -18.9 M
Other Expenses -10.6 M
Net Income -8.32 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)2m(78k)2m(21m)(19m)11m(8m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
96.16% GROSS MARGIN
96.16%
-931.17% OPERATING MARGIN
-931.17%
-409.85% NET MARGIN
-409.85%
-87.48% ROE
-87.48%
-45.36% ROA
-45.36%
-161.35% ROIC
-161.35%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis DURECT Corporation
image
15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -8.32 M
Depreciation & Amortization 84 K
Capital Expenditures 0
Stock-Based Compensation 2 M
Change in Working Capital -1.92 M
Others -11.6 M
Free Cash Flow -19.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets DURECT Corporation
image
DRRX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership DURECT Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript DURECT Corporation (NASDAQ:DRRX ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Co-Founder, Chief Executive Officer, President, Director Norman Sussman - Chief Medical Officer WeiQi Lin - Executive Vice President, Research & Development and Principal Scientist Conference Call Participants François Brisebois - Oppenheimer & Company Karl Burns - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Greetings and welcome to the DURECT Corporation Fourth Quarter and Full-Year 2024 Earnings Conference Call. seekingalpha.com - 1 month ago
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates Durect (DRRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.27 per share a year ago. zacks.com - 1 month ago
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif. prnewswire.com - 1 month ago
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update CUPERTINO, Calif. , March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. prnewswire.com - 1 month ago
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. prnewswire.com - 2 months ago
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial CUPERTINO, Calif. , Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. prnewswire.com - 3 months ago
Durect (DRRX) Upgraded to Strong Buy: Here's Why Durect (DRRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
New Strong Buy Stocks for January 9th AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024. zacks.com - 3 months ago
Durect (DRRX) Upgraded to Buy: Here's What You Should Know Durect (DRRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 4 months ago
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P. prnewswire.com - 5 months ago
DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript DURECT Corporation (NASDAQ:DRRX ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jim Brown - Co-Founder, Chief Executive Officer, President, Director Tim Papp - Chief Financial Officer WeiQi Lin - Executive Vice President of Research and Development, Principal Scientist Conference Call Participants Thomas Yip - H.C. Wainwright Karl Burns - Northland Capital Markets Operator Greetings! seekingalpha.com - 5 months ago
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates Durect (DRRX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.40 per share a year ago. zacks.com - 5 months ago
8. Profile Summary

DURECT Corporation DRRX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 22.9 M
Dividend Yield 0.00%
Description DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Contact 10260 Bubb Road, Cupertino, CA, 95014-4166 https://www.durect.com
IPO Date Sept. 28, 2000
Employees 21
Officers Dr. Su Il Yum Ph.D. Executive Officer Mr. Timothy M. Papp M.B.A. Chief Financial Officer & Secretary Dr. James E. Brown D.V.M. Co-Founder, Chief Executive Officer, President & Director Dr. WeiQi Lin M.D., Ph.D. Executive Vice President of Research & Development and Principal Scientist Ms. Judy R. Joice Senior Vice President of Operations & Corporate Quality Assurance Ms. Jian Li M.B.A. Senior Vice President of Finance, Corporate Controller & Secretary Dr. Norman L. Sussman M.D. Chief Medical Officer